{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:46:16Z","timestamp":1774449976201,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In rapidly progressing cancers, appropriate selection of first-line therapy is essential in prolonging survival. Alongside immunohistochemistry (IHC), comprehensive genomics, including whole exome and transcriptome sequencing (WES\/WTS), can improve diagnostic accuracy and guide therapeutic management. Here, we report a young patient with rapidly progressing malignancy and unexpected post-mortem results, a scenario that may have been altered by early, comprehensive genomic sequencing. A 43-year-old man with no relevant medical history presented to the emergency department with progressive cough and dyspnea despite treatment for pneumonia. Radiology revealed enlarged subcarinal, hilar, retroperitoneal, and mesenteric lymph nodes, suspicious for metastasis, and a right kidney mass. Pathologic analysis of a retroperitoneal lymph node was felt to be most consistent with metastatic epithelioid angiomyolipoma (mEAML). Three weeks later, he was urgently treated with an mTOR inhibitor for presumed mEAML due to rapid clinical decline, and a subsequent 4R lymph node biopsy was performed to confirm the diagnosis and identify genomic targets via IHC and WES\/WTS. Unfortunately, he developed hypoxic respiratory failure, and only posthumously did WES\/WTS reveal pathogenic variants in BAP1 and VHL, consistent with clear cell renal cell carcinoma (ccRCC).<\/jats:p>\n               <jats:p>With an earlier ccRCC diagnosis, he would have received combination immunotherapy\/tyrosine kinase inhibition, which has significantly greater activity than mTOR inhibition in ccRCC. He could have received systemic treatment earlier, with optimal therapy, while potentially carrying lower tumor burden and greater clinical stability. In cases of rapidly progressing malignancies with complex histopathological presentations, early comprehensive molecular-based testing can aid in diagnosis and critical therapeutic decision-making.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad280","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T23:03:34Z","timestamp":1697497414000},"page":"1094-1099","source":"Crossref","is-referenced-by-count":2,"title":["A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3697-9623","authenticated-orcid":false,"given":"Daniel E","family":"McLoughlin","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"},{"name":"Termeer Center for Targeted Therapies, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Chevalier","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"},{"name":"Termeer Center for Targeted Therapies, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9896-8084","authenticated-orcid":false,"given":"Edwin","family":"Choy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-9302","authenticated-orcid":false,"given":"Gregory M","family":"Cote","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"},{"name":"Termeer Center for Targeted Therapies, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"},{"name":"Termeer Center for Targeted Therapies, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Juric","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"},{"name":"Termeer Center for Targeted Therapies, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-654X","authenticated-orcid":false,"given":"Kerry L","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2023122612592612800_CIT0001","first-page":"7","article-title":"Cancer statistics, 2022","volume-title":"CA Cancer J Clin","author":"Siegel","year":"2022"},{"key":"2023122612592612800_CIT0002","first-page":"40","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume-title":"JAMA Oncol","author":"Ross","year":"2015"},{"key":"2023122612592612800_CIT0003","first-page":"235","article-title":"Renal epithelioid angiomyolipoma mimicking urothelial carcinoma of the upper urinary tract","volume-title":"Arch Ital Urol Androl","author":"Adanur","year":"2014"},{"key":"2023122612592612800_CIT0004","first-page":"133","article-title":"Epithelioid angiomyolipoma of the kidney mimicking renal cell carcinoma: a clinicopathologic analysis of cases and literature review","volume-title":"Kaohsiung J Med Sci","author":"Tsai","year":"2009"},{"key":"2023122612592612800_CIT0005","first-page":"e178","article-title":"Renal epithelioid angiomyolipoma: a case report and review of literature","volume-title":"Oman Med J","author":"Al Umairi","year":"2020"},{"key":"2023122612592612800_CIT0006","first-page":"610858","article-title":"Everolimus in invasive malignant renal epithelioid angiomyolipoma","volume-title":"Front Oncol","author":"Guo","year":"2020"},{"key":"2023122612592612800_CIT0007","first-page":"823","article-title":"Comprehensive clinical and pathological analysis of aggressive renal epithelioid angiomyolipoma: report of three cases","volume-title":"Onco Targets Ther","author":"Luo","year":"2014"},{"key":"2023122612592612800_CIT0008","first-page":"1361","article-title":"Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms","volume-title":"Hum Pathol","author":"Kenerson","year":"2007"},{"key":"2023122612592612800_CIT0009","first-page":"S139","article-title":"Case report of everolimus-induced sustained partial response in metastatic renal epithelioid angiomyolipoma","volume-title":"Turk J Urol","author":"Tayal","year":"2019"},{"key":"2023122612592612800_CIT0010","first-page":"817","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume-title":"Lancet","author":"Bissler","year":"2013"},{"key":"2023122612592612800_CIT0011","first-page":"2271","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume-title":"N Engl J Med","author":"Hudes","year":"2007"},{"key":"2023122612592612800_CIT0012","first-page":"1289","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume-title":"N Engl J Med","author":"Motzer","year":"2021"},{"key":"2023122612592612800_CIT0013","first-page":"187","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume-title":"JCO Oncol Pract","author":"Tran","year":"2022"},{"key":"2023122612592612800_CIT0014","first-page":"103030","article-title":"CUP-AI-Dx: a tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence","volume-title":"EBioMedicine","author":"Zhao","year":"2020"},{"key":"2023122612592612800_CIT0015","first-page":"101016","article-title":"Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type","volume-title":"Transl Oncol","author":"Abraham","year":"2021"},{"key":"2023122612592612800_CIT0016","first-page":"217","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute","volume-title":"J Clin Oncol","author":"Hainsworth","year":"2013"},{"key":"2023122612592612800_CIT0017","first-page":"525","article-title":"Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors","volume-title":"JAMA Oncol","author":"Cobain","year":"2021"},{"key":"2023122612592612800_CIT0018","first-page":"435","article-title":"Genomic profiling in renal cell carcinoma","volume-title":"Nat Rev Nephrol","author":"Dizman","year":"2020"},{"key":"2023122612592612800_CIT0019","first-page":"718","article-title":"BAP1-mutated clear cell renal cell carcinoma","volume-title":"Am J Clin Pathol","author":"Gallan","year":"2021"},{"key":"2023122612592612800_CIT0020","first-page":"46","article-title":"Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies","volume-title":"Oncologist","author":"Shuch","year":"2012"},{"key":"2023122612592612800_CIT0021","first-page":"539","article-title":"The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications","volume-title":"Nat Rev Urol","author":"Linehan","year":"2019"},{"key":"2023122612592612800_CIT0022","first-page":"12","article-title":"PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma","volume-title":"J Clin Pathol","author":"Barr","year":"2015"},{"key":"2023122612592612800_CIT0023","first-page":"7146","article-title":"Carbonic anhydrase IX in renal cell carcinoma, implications for disease management","volume-title":"Int J Mol Sci","author":"Courcier","year":"2020"},{"key":"2023122612592612800_CIT0024","first-page":"529","article-title":"Comprehensive molecular profiling broadens treatment options for breast cancer patients","volume-title":"Cancer Med","author":"Kawaji","year":"2021"},{"key":"2023122612592612800_CIT0025","first-page":"114","article-title":"Importance of comprehensive molecular profiling for clinical outcome in children with recurrent cancer","volume-title":"Front Pediatr.","author":"Ostrup","year":"2018"},{"key":"2023122612592612800_CIT0026","first-page":"898","article-title":"Impact of next generation sequencing on clinical practice in oncology in France: better genetic profiles for patients improve access to experimental treatments","volume-title":"Value Health","author":"Coquerelle","year":"2020"},{"key":"2023122612592612800_CIT0027","first-page":"1122","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume-title":"Genet Med","author":"Schwarze","year":"2018"},{"key":"2023122612592612800_CIT0028","first-page":"1107","article-title":"Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing","volume-title":"J Genet Couns","author":"Reuter","year":"2019"},{"key":"2023122612592612800_CIT0029","article-title":"What are patient assistance programs","author":"Chase","year":"2022"},{"key":"2023122612592612800_CIT0030","first-page":"533","article-title":"Application of next-generation sequencing to improve cancer management: a review of the clinical effectivenessand cost-effectiveness","volume-title":"Clin Genet","author":"Tan","year":"2017"},{"key":"2023122612592612800_CIT0031","first-page":"207","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis","volume-title":"Lung Cancer","author":"Tan","year":"2020"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/12\/1094\/54874964\/oyad280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/12\/1094\/54874964\/oyad280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T12:59:52Z","timestamp":1703595592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/12\/1094\/7319338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,10,16]]},"published-print":{"date-parts":[[2023,12,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad280","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,10,16]]}}}